Dr. Reddy's Laboratories logo
Dr. Reddy's Laboratories
RDY | NYSE
Chart Builder DCF Calculator
$14.70
-$0.04 (-0.27%)
At close: Nov 16, 2026, 4:00 PM ET
$14.70
$0.00 (0.00%)
After-hours: Nov 16, 2026, 5:46 PM ET

Dr. Reddy's Laboratories Company Profile

Company profile explained

Company Profile

Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. The Global Generics segment is responsible for the manufacturing and sale of both prescription and over-the-counter finished pharmaceutical products. These offerings are available either under a proprietary brand or as generic formulations that are therapeutically identical to their branded equivalents. This segment also includes the company's biologics ventures. The Pharmaceutical Services and Active Ingredients (PSAI) division focuses on producing and distributing active pharmaceutical ingredients (APIs) and chemical intermediates, which serve as crucial building blocks for final drug products. Additionally, PSAI provides contract research services and produces custom-specified APIs and steroids for clients. The Proprietary Products segment is dedicated to the research and advancement of unique pharmaceutical formulations. The Others segment is actively involved in developing treatments, primarily for oncology (cancer) and inflammatory conditions. Dr. Reddy's addresses a broad spectrum of therapeutic areas, including gastrointestinal issues, cardiovascular health, diabetes, dermatological concerns, cancer, respiratory diseases, oral health, urological disorders, and nephrological conditions. The company has also established a partnership with Curis, Inc., centered on the discovery, development, and commercialization of small molecule antagonists designed for immuno-oncology and precision oncology targets. Founded in 1984, Dr. Reddy's Laboratories Limited maintains its principal office in Hyderabad, India.

Key Executives

Name Position
Deepak Sapra CEO – API and Services & Member of Management Council
Erez Israeli Chief Executive Officer & Member of the Management Council
Milan Kalawadia Chief Executive Officer of North America & Member of Management Council
Motupalli Venkata Ramana CEO of Global Generics & Member of Management Council
Mannam Venkatanarasimham Chief Financial Officer & Member of the Management Council
Bhethanabottla S. Phanimitra Chief Digital and Information Officer & Member of the Management Council
Gunupati Venkateswara Prasad Co-Chairman, MD & Member of Management Council
Kallam Satish Reddy Chairman of the Board & Member of the Management Council
Krishna K. Venkatesh B.Pharma Global Head of IPDO, Integrated Product Development & Member of the Management Council
Patrick Aghanian Head of Consumer Health Organization & Member of Management Council
Sanjay Sharma Executive VP, COO & Member of Management Council

Latest SEC Filings

Date Type Title
Oct 29, 2026 6-K Filing
Oct 29, 2026 6-K Filing
Oct 26, 2026 6-K Filing
Oct 26, 2026 6-K Filing
Oct 23, 2026 6-K Filing
Oct 23, 2026 6-K Filing
Oct 23, 2026 6-K Filing
Oct 23, 2026 6-K Filing
Oct 21, 2026 6-K Filing
Oct 14, 2026 6-K Filing
View All SEC Filings ➞
Dr. Reddy's Laboratories
Dr. Reddy's Laboratories logo
Country India
IPO Date Apr 11, 2001
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 27,527
CEO Erez Israeli

Contact Details

8-2-337, Road No. 3 Hyderabad, TS 500034 India

Stock Details

Ticker Symbol RDY
Exchange NYSE
Fiscal Year April - March
Reporting Currency USD
CIK Code 0001135951
CUSIP Number 256135203
ISIN Number US2561352038
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.